Cyproheptadine as an Appetite Stimulant

St. Justine's Hospital20 enrolled

Overview

Cyproheptadine is currently clinically used as an appetite stimulant for children with failure to thrive without underlying organic disease. Otherwise, no randomised control trial demonstrates the efficacy of Cyproheptadine on those patients. This is precisely what the investigators intend to demonstrate on this randomised placebo control cross-over trial. Our hypothesis is that Cyproheptadine is more efficient than placebo to improve weight gain and feeding behaviour on 2 to 4 years old children with failure to thrive.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Failure to Thrive

Interventions

CyproheptadineDRUG

0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month

Sugar pillDRUG

liquid placebo

Eligibility

Sex: ALLMin age: 2 YearsMax age: 4 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 2 to 4 years of age * failure to thrive Exclusion Criteria: * Medication affecting appetite * Medication interacting with Cyproheptadine * Prematurity under 36 weeks of gestation * Neurologic impairment * underlying organic disease

Locations (1)

Ste-Justine University Health Center

Montreal, Quebec, Canada

RECRUITING

Outcomes

Primary Outcomes

Weight gain

Time frame: January 2011 to January 2012

Secondary Outcomes

Feeding behaviour

Time frame: January 2011 to January 2012

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.